… in metastatic colorectal cancer with … checkpoint inhibitors in colorectal cancer. While
identification of predictive biomarkers of immune checkpoint inhibitor efficacy in colorectal cancer is …

… , checkpoint-blocking antibodies have shown promising outcomes in CRC patients by blocking
inhibitory immune checkpoints … recent advances in immune checkpoint inhibitors (ICIs), …

… immune checkpoint inhibitors … colorectal cancer generally has a tumor microenvironment
with infiltration of T cells, associated with a favorable response to immune checkpoint inhibitors. …

… response to immune checkpoint inhibitors with dramatic … response to immune checkpoint
inhibitor treatment points to … the efficacy of immune checkpoint inhibitors in patients with MSI-H/…

… —all checkpoint inhibitors—are … checkpoint inhibitor therapies. Using a question‐and‐answer
format, this review summarizes the scientific rationale for immune checkpoint inhibitor …

… Immune checkpoint inhibitors (ICIs), as a subverter of immunotherapy in oncology, are … on
melanoma and non-small cell lung cancer (NSCLC). For colorectal cancer (CRC), only a small …

… Colorectal cancers (CRCs) remain one of the most common and challenging neoplasia in …
’s approval of both immune checkpoint inhibitors (ICIs) pembrolizumab and nivolumab in the …

… Colorectal cancer (CRC) is ranked as the third cause of cancer death worldwide. The
progression to the metastatic stage cuts down the overall survival rate to 10%. Advances in …

… We present an updated review of the biological background and clinical development of
immune checkpoint inhibitors in colorectal cancer (CRC). Early trial results on PD1 and PD-L1 …

The long-term remissions induced by immune-checkpoint inhibitors (ICIs) in many types of
cancers have opened up the possibility of a broader use of immunotherapy in less …